Camp4 Therapeutics (CAMP) Proxy filing summary

Executive summary

• The annual meeting will be held virtually on June 11, 2025, with voting on director elections and auditor ratification.

• Stockholders of record as of April 14, 2025, are eligible to vote, with 20,161,073 shares outstanding.

• The company completed its IPO in October 2024, raising $82.1 million gross proceeds.

• Proxy materials are distributed electronically to conserve resources and reduce costs.

Voting matters and shareholder proposals

• Stockholders will vote to elect four Class I directors for three-year terms and to ratify Ernst & Young LLP as the independent auditor for 2025.

• Board recommends voting FOR all director nominees and auditor ratification.

• Shareholder proposals for the 2026 meeting must be submitted by December 31, 2025, for proxy inclusion.

Board of directors and corporate governance

• Board consists of eleven members post-meeting, divided into three classes with staggered three-year terms.

• Majority of directors are independent under Nasdaq rules; CEO is not independent.

• Board committees include audit, compensation, and nominating/governance, each with defined charters and responsibilities.

• Board held five meetings in 2024, with at least 75% attendance by all directors.

• Code of Business Conduct and Ethics and insider trading policy are in place.